Investors reward Fate for off-the-shelf NK data at ASH

Fate’s 41% gain following presentations at ASH solidifies its iPS cell-derived NK platform’s status as the company’s center of gravity. The company is advancing a series of increasingly complex off-the-shelf NK cell therapies, with a thrice-modified candidate slated to enter the clinic early next year.

Fate Therapeutics Inc. (NASDAQ:FATE) gained $5.65 to $19.32 Monday for a gain of nearly $430 million in market cap after announcing results for its two induced pluripotent stem (iPS) cell clinical candidates FT-500 and FT-516 on Saturday, and next-in-line program FT-596 on Sunday. ...